BiotechTube

avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thrombocytopenia Associated With Liver Disease

Conditions

Thrombocytopenia Associated With Liver Disease

Trial Timeline

Feb 1, 2014 → Feb 27, 2017

NCT ID
NCT01972529

About avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)

avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count) is a phase 3 stage product being developed by Eisai for Thrombocytopenia Associated With Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01972529. Target conditions include Thrombocytopenia Associated With Liver Disease.

What happened to similar drugs?

2 of 20 similar drugs in Thrombocytopenia Associated With Liver Disease were approved

Approved (2) Terminated (2) Active (16)
✅Standard heparin (UFH) versus certoparin (LMWH)NovartisApproved
✅romiplostimAmgenApproved
🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
🔄Avatrombopag + Placebo + Standard of careEisaiPhase 3
🔄Romiplostim + PlaceboKyowa KirinPhase 3
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
🔄Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01972529Phase 3Completed
NCT01976104Phase 3Completed

Competing Products

20 competing products in Thrombocytopenia Associated With Liver Disease

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
35
avatrombopagEisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
avatrombopag + PlaceboEisaiPhase 2
35
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + RibavirinEisaiPhase 2
35
Avatrombopag + Placebo + Standard of careEisaiPhase 3
40
RomiplostimKyowa KirinPhase 1/2
32
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
ONO-7746Ono PharmaceuticalPhase 1
21
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
47
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
42
TPO-RA (Herombopag) + TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)Jiangsu Hengrui MedicinePhase 2
31